As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…
In an internal memo seen by TechCrunch, VSCO’s CEO Eric Wittman said the company’s consumer business had declined more than expected, and some of its new growth initiatives didn’t yield the expected results.